c2ccc6b3-34d8-47c5-9367-cc53aad1622e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- IL6_JAK_STAT3_SIGNALING+0.500
- NOTCH_SIGNALING+0.500
- PROTEIN_SECRETION+0.500
- TGF_BETA_SIGNALING+0.500
- TNFA_SIGNALING_VIA_NFKB+0.500
- UV_RESPONSE_DN+0.500
- INFLAMMATORY_RESPONSE+0.400
- KRAS_SIGNALING_UP+0.400
Top 10 suppressed
- E2F_TARGETS-0.600
- MYC_TARGETS_V2-0.600
- G2M_CHECKPOINT-0.500
- DNA_REPAIR-0.400
- MYC_TARGETS_V1-0.400
- SPERMATOGENESIS-0.300
- ESTROGEN_RESPONSE_LATE-0.200
- INTERFERON_ALPHA_RESPONSE-0.200
- KRAS_SIGNALING_DN-0.200
- FATTY_ACID_METABOLISM-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-46-3767-01A-01R-0980-07 | — | cohortSQ1 | 0.901 |
| 2 | ERR2208941 | — | — | 0.892 |
| 3 | TCGA-73-4658-01A-01R-1755-07 | — | cohortA1 | 0.883 |
| 4 | TCGA-BA-5557-01A-01R-1514-07 | — | — | 0.880 |
| 5 | GSM6454738 | — | A | 0.877 |
| 6 | TCGA-K4-A4AB-01B-12R-A28M-07 | — | — | 0.866 |
| 7 | TCGA-E9-A1NG-01A-21R-A14M-07 | — | A | 0.865 |
| 8 | TCGA-BH-A1EO-01A-11R-A137-07 | — | A | 0.865 |
| 9 | TCGA-AO-A0JF-01A-11R-A056-07 | — | A | 0.862 |
| 10 | TCGA-DQ-5624-01A-01R-1873-07 | — | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.500 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |